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pensate for the bone loss of adynamic bone 
disease.14 The clinically important question 
of whether adynamic bone disease is asso-
ciated with enhanced fracture risk has not 
been answered unequivocally.15,16 There-
fore, if bone is being formed de novo at 
trabecular sites important for bone stat-
ics, even small bone mass gains are prob-
ably beneficial. Chen et al. indicate that 
alfacalcidol induces minimodeling in rats 
at unique sites called boutons.13 These 
boutons connect adjacent trabeculae and 
increase trabecular thickness. Whether 
this leads to enhanced physical bone sta-
bility remains to be shown in large clinical 
or animal studies. However, currently it is 
tempting to speculate that the continuous 
application of vitamin D compounds might 
preserve bone mass in adynamic bone dis-
ease irrespective of their inhibitory effects 
on PTH synthesis. In this regard, different 
vitamin D derivatives—including 25OH-
vitamin D—could exhibit different effects 
and magnitudes of action. Consequently, 
to benefit from the potentially favorable 
impact of minimodeling, future K/DOQI 
guidelines might well recommend the con-
tinuation of some vitamin D sterols even in 
the presence of low PTH levels. The effect 
of calcimimetics on bone stability and frac-
ture rate was analyzed with a major portion 
of patients taking vitamin D sterols.17 As 
the treatment with calcimimetics lowers 
PTH levels, the bone-preserving effect 
might also—at least partially—depend on 
the additional action of some vitamin D 
derivative to induce and maintain mini-
modeling. It will be interesting to follow 
the course of future research in this field, 
which will certainly aim to fill this and 
other gaps in our knowledge.
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Let’s look at cysts  
from both sides now
Seth L. Alper1
In the years since identification of autosomal-dominant polycystic 
kidney disease (ADPKD) genes, the lag time between initial 
understanding and translation to therapy has decreased rapidly. 
Albaqumi and colleagues describe a promising approach to slow ADPKD 
cyst enlargement through inhibition of the basolateral KCa3.1 K+ 
channel, using a nontoxic small molecule with a close congener poised 
for rapid entry into the clinic. Cyst fluid accumulation can be blocked 
from both sides now.
Kidney International (2008) 74, 699–702. doi:10.1038/ki.2008.357
Autosomal-dominant polycystic kid-
ney disease (ADPKD) is the most com-
mon lethal monogenic disease, affecting 
between 0.025% and 0.25% of studied 
populations. The autosomal-dominant pat-
tern arises from a germline mutation and 
one or more hypothesized somatic second 
hits that may be allelic or oligogenic, lead-
ing to metaplastic change from epithelial 
tubule to cyst in 1%–3% of nephrons. 
Cystogenesis is accompanied by (and may 
arise from) ciliary dysfunction and loss of 
epithelial planar polarity in the context of 
accelerated proliferation and dedifferentia-
tion, either early in renal development or 
in the setting of (often subclinical) renal 
injury and repair. Cysts increase in size 
at a stable rate of 5%–6% per year, with 
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progression to end-stage renal disease 
in about 50% of patients1 attributed to 
cyst-induced compression and vascular 
compromise of adjacent, unaffected renal 
parenchyma. As cyst volume and total kid-
ney volume are the strongest predictors of 
disease progression,2 slowing or stopping 
cyst growth is a major objective of treat-
ment. This objective has been approached 
through exploitation of inhibitors of pas-
sage through the cell cycle and through 
development of ion transport inhibitors to 
block the dysregulated Cl– secretion driving 
cyst enlargement. Blockade of cyst enlarge-
ment through inhibition of ion transport 
has to date included vasopressin receptor 
antagonists, a somatostatin receptor ago-
nist, and, most recently, antagonists of the 
apical cyclic AMP (cAMP)-sensitive Cl– 
channel CFTR (cystic fibrosis transmem-
brane conductance regulator). Albaqumi 
et al.3, in the laboratory of Edward Skol-
nik [with their collaborators, Wulff and 
Wallace] (this issue), now add to this list 
another strategy, that of basolateral K+ 
channel inhibition.
The long, tortuous tubule that forms 
the postglomerular nephron exploits axial 
heterogeneity and a countercurrent mul-
tiplier system to reabsorb 98%–99% of 
glomerular filtrate. However, the develop-
mentally disordered epithelial cells of the 
closed ADPKD cyst express a metaplastic 
phenotype of Cl– secretion mediated by 
coordinated activity of the apical cAMP-
sensitive Cl– channel CFTR and the basola-
teral Na/K/2Cl cotransporter NKCC1. Also 
essential to sustained, transepithelial Cl– 
secretion are basolateral recycling of Na+ 
and K+ and maintenance of a hyperpolar-
ized membrane potential by the basolateral 
Na+,K+-ATPase and by K+ channels such 
as the Ca2+-dependent K+ channel KCa3.14 
(Figure 1). The hyperpolarization serves 
to turn off short-lived Ca2+ entry through 
depolarization-activated CaV Ca2+ chan-
nels while sustaining prolonged Ca2+ 
entry through transient receptor potential 
(TRP)-like ligand-operated cation chan-
nels and through Orai/Stim store-operated 
Ca2+ channels.
A urinary-concentrating defect is perhaps 
the earliest clinical manifestation of ADPKD 
and is often accompanied by elevated serum 
vasopressin levels. The vasopressin-2 recep-
tor (V2R) is the major source of renal cAMP, 
and cAMP is elevated in ADPKD kidneys 
and cyst fluids. ADPKD cyst epithelial 
cells proliferate and cysts grow in response 
to cAMP, in contrast to cAMP-induced 
growth inhibition of normal kidney epithe-
lial cells. This group of observations has led 
to impressive demonstrations of cyst growth 
retardation in rodent models of polycystic 
kidney disease, most impressively in the 
demonstration that the genetic absence of 
arginine vasopressin in the Brattleboro rat 
protects dramatically against cyst growth in 
the Pcy rat model of polycystic kidney dis-
ease.5 V2R inhibition may also afford inde-
pendent protection against hypertension 
and progressive loss of renal function. V2R 
antagonists have entered phase 3 clinical 
trials, but the attendant polyuria may prove 
taxing for some patients. Moreover, as V2R 
is expressed in the collecting duct, the ability 
of V2R antagonists to retard growth of cysts 
of proximal origin remains uncertain.
A distinct strategy to lower renal cAMP 
and retard cyst enlargement by inhibition 
of Cl– secretion is blockade of renal SSTR2 
somatostatin receptors. A 6-month trial of 
a clinically approved, long-acting somato-
statin analogue, octreotide, was associated 
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figure 1 | Inhibition of cyst epithelial cell Cl– secretion from both sides now. Schematic of 
polarized autosomal-dominant polycystic kidney disease (ADPKD) cyst epithelial cell, depicting 
transporters and signaling pathways involved in cyst Cl– secretion. Cl– secretion into the cyst 
lumen (top) requires Cl– entry into the cyst cell across its basolateral membrane via the Na+/
K+/2Cl– cotransporter NKCC1, and Cl– exit from the cyst cell across its apical membrane via protein 
kinase A (PKA)-stimulated cystic fibrosis transmembrane conductance regulator (CFTR). Secretion 
is under stimulatory control of cyclic AMP (cAMP) generated by the vasopressin-2 receptor (V2R), 
modulated by the inhibitory somatostatin-2 receptor (SSTR2) and by stimulatory Ca2+-signaling 
pathways involving phospholipase C-γ (PLCγ), inositol-triphosphate (IP3), and other messengers. This 
Cl–-secretory process requires basolateral recycling of K+ via KCa3.1 and of Na+ via Na+, K+-ATPase. 
Elevated cytosolic Ca2+ required for KCa3.1 activation can derive from endoplasmic reticulum (ER) 
stores via ryanodine receptors (RyR), IP3 receptors (IP3R), and polycystin-2 (PC2). Activating Ca
2+ can 
also enter from extracellular fluid via transient receptor potential (TRP) channels, including PC2 in 
complex with polycystin-1 (PC1) in the flow-sensitive monocilium (top), or in basolateral membrane, 
store-operated channels (Orai) in complex with near-surface ER-localized Stim1, or via voltage-gated 
Ca2+ channels (CaV). Cl– secretion into the cyst lumen can be blocked at the basolateral membrane by 
the KCa3.1 inhibitors senicapoc and TRAM-34 (ref. 3) (lower left) and at the apical membrane by CFTR 
antagonists (upper right). Cl– secretion can also be inhibited by V2R antagonists and somatostatin 
analogues (lower right); PKA’s role in cAMP stimulation of cyst epithelial KCa3.1 is uncertain. Ca2+, 
calcium ion; Cl– , chloride ion; Gi, inhibitory Gα protein; Gs, stimulatory Gα protein; R, receptors for 
various hormones; TJ, tight junction. (Adapted with permission from ref. 1.)
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in 12 ADPKD patients with only 50% of 
the kidney volume increase observed in 
placebo controls.6
Direct inhibition of the channels and 
transporters responsible for Cl– secretion 
into the cyst has been a long-held goal. 
CFTR’s role in cyst Cl– secretion has been 
suggested by a reduced rate of renal disease 
progression in some of the rare patients 
afflicted with both cystic fibrosis and ADP-
KD.7 The long absence of specific inhibi-
tors for the CFTR Cl– channel in the cyst 
epithelial cell apical membrane has been 
remedied by Verkman and colleagues.8,9 
They have recently shown that inhibitors 
of improved aqueous solubility inhibited 
cyst expansion in MDCK cells and in 
cAMP-stimulated embryonic mouse kid-
ney culture at concentrations comparable 
to those that inhibit electrogenic chloride 
secretion by MDCK monolayers. Most 
dramatically, systemic treatment of new-
born Pkd1flox/–;Ksp-Cre mice with CFTR 
inhibitors slowed cyst growth and attenu-
ated the decline in renal function in this 
early-onset rapidly progressive ADPKD 
model.10 Since transgene correction stud-
ies suggest that as little as 10% of CFTR 
function may suffice for health, potential 
pulmonary and intestinal side effects of 
chronic CFTR inhibition may be minimal 
in ADPKD patients. However, potential 
secondary pancreatitis and bronchitis 
remain of concern.11
Transporters and channels of the cyst 
epithelial cell basolateral membrane 
should also serve as targets for inhibi-
tion of transepithelial Cl– secretion. 
Targeting of basolateral Na+,K+-ATPase 
with digoxin, or of the basolateral Na+/
K+/2Cl– cotransporter NKCC1 with 
loop diuretics, has been thought likely 
to be accompanied by unacceptable side 
effects. However, Albaqumi et al.3 have 
now provided proof of principle for the 
widely expressed KCa3.1 intermediate-
conductance K+ channel as such a target 
in ADPKD (Figure 1). KCa3.1 is inhibited 
by clotrimazole12–14 and other imidazole 
antifungals at nanomolar concentrations, 
but higher doses in phase 1 subjects ele-
vated liver function tests,15 an effect attrib-
uted to the drug’s imidazolyl group, which 
inhibits the fungal cytochrome ergosterol 
synthase. The trityl group contributes to 
channel inhibition, and des-imidazolyl 
trityl derivatives exhibit high channel spe-
cificity without side effects.16,17 One such 
KCa3.1 inhibitor, senicapoc (ICA-17043), 
has been used successfully in 55 patients in 
a 12-week phase 2 trial18 to block KCa3.1 
in sickle erythrocytes. Treatment led to 
increased mean corpuscular volume, 
decreased mean corpuscular hemoglobin 
concentration, and decreased hemolysis 
with increased hematocrit. Additional 
patients experienced little or no toxicity 
over longer periods in a phase 3 trial.19 
The grossly healthy KCa3.1 knockout 
mice20 are refractory to diarrheagenic 
stimuli21 but develop mild to moderate 
hypertension.22 However, hypertension 
was absent from sickle disease patients 
treated with senicapoc.18
Albaqumi et al.3 used the des-imidazolyl 
clotrimazole analogue TRAM-34 and the 
nonspecific KCa3.1 agonist DCEBIO to 
confirm that MDCK cells, primary nor-
mal human kidney (NHK) cells, and pri-
mary human ADPKD cyst cells exhibit 
whole-cell Ca2+-activated K+ currents 
with properties of KCa3.1. Small interfer-
ing RNA knockdown confirmed KCa3.1 as 
the mediator of this TRAM-34-sensitive, 
DCEBIO-stimulated K+ current in MDCK 
cells. In filter-grown polarized monolay-
ers of MDCK, NHK, and ADPKD cells, 
TRAM-34 also inhibited forskolin- 
stimulated transepithelial Cl– secretion 
measured as short-circuit current. Inhi-
bition was lost in basolateral nystatin- 
permeabilized monolayers of normal 
human renal epithelial cells and ADPKD 
cells, consistent with TRAM-34 action 
on basolateral KCa3.1 rather than on api-
cal CFTR. These results recalled earlier 
demonstrations of inhibition of agonist-
stimulated transepithelial Cl– secretion 
by inhibition of basolateral KCa3.1 in 
polarized T84 intestinal cell monolayers, 
intact intestinal mucosa,23,24 and respira-
tory cell monolayers.25 Finally, Albaqumi 
et al.3 showed that chronic exposure to 
TRAM-34 concentrations that do not 
inhibit cAMP-induced proliferation of 
serum-starved cells inhibit MDCK cell 
and ADPKD cell cyst formation and 
enlargement in collagen gels containing 
forskolin and epidermal growth factor by 
nearly 90%. Cyst formation and enlarge-
ment were also effectively inhibited by 
the endogenous KCa3.1 inhibitor myo-
tubularin-related protein-6 in a manner 
requiring its intrinsic phosphatidylinosi-
tol-3-phosphatase activity.
TRAM-34 will soon be tested for its 
ability to retard cyst growth and disease 
progression in mouse models of poly-
cystic kidney disease. The KCa3.1-null 
genotype is also being bred into mouse 
polycystic kidney disease models. With 
or without indication of efficacy in mouse 
models, the apparently nontoxic senica-
poc may soon be brought to clinical trial 
for ADPKD. KCa3.1 inhibition also shows 
promise in the treatment of toxigenic and 
inflammatory diarrhea, preclinical mod-
els of asthma, autoimmune and inflam-
matory disorders, cancer xenografts, 
transplantation,26 and arteriosclerosis.27 
Thus KCa3.1 inhibitors hold promise 
not only for sickle disease and ADPKD 
but may also find broad application as 
treatments for a host of diseases in which 
KCa3.1 dysregulation alters cell mem-
brane potential and volume, leading to 
altered cell activation, cell motility, and 
altered programs of gene transcription.
Additional studies will be needed to 
address the possible consequence to 
cystogenesis of successful ion transport 
inhibition. In the meantime, ADPKD cyst 
growth retardation can be approached 
“from both sides now,” by combined 
blockade of apical membrane CFTR and 
of basolateral membrane KCa3.1, per-
haps reinforced by V2R blockade and/or 
somatostatin agonists. With these emerg-
ing therapies, in concert with the target-
of-rapamycin kinase inhibitor rapamycin, 
the cyclin-dependent kinase inhibitor ros-
covitine, and other drugs under current 
investigation, nephrologists can now real-
istically envision the lives of their ADPKD 
patients without progression to end-stage 
renal disease and the many complications 
encountered along the way.
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PPAR-γ and aging:  
one link through klotho?
Ruihua Zhang1 and Feng Zheng1
PPAR-γ, a transcription factor involved in adipogenesis, glucose 
homeostasis, bone turnover, and inflammation, has now been shown to 
increase klotho expression. Klotho is predominantly expressed by the 
kidney and functions at the tubule and in the circulation as an anti-aging 
factor and a hormone participating in mineral metabolism. The finding 
that klotho is upregulated by PPAR-γ may prompt further exploration of 
the role and mechanism of action of PPAR-γ  in aging and bone diseases.
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Aging is an inevitable but an extendable 
process. Both exogenous and endogenous 
factors may change the course of 
biological aging. For instance, calorie 
restriction has been consistently shown 
to prolong life span, from lower organ-
isms to primates. Additionally, mutation, 
deletion, or overexpression of evolution-
arily conserved molecules involved in 
the growth hormone/insulin/insulin-like 
growth factor-1 (IGF-1) signaling path-
way alters the aging process.1
Oxidative stress, caused by an imbalance 
between oxidant production and antioxi-
dants, is widely believed to be a central 
player in aging. While the production of 
reactive free radicals is absolutely required 
for host defenses and normal cell functions, 
the presence of detoxificants, including 
superoxide dismutase, catalase, glutathione 
peroxidase, and glutathione reductase, 
is critical in maintaining a normal redox 
state and in cell life-and-death decisions 
during stress. It is known, for example, that 
the prosurvival action of nuclear factor-κB 
is partly mediated by its increasing of the 
transcription of super oxide dismutase and 
catalase. The upregulation of antioxidants 
also contributes to the anti-aging function 
of the forkhead box O (FOXO) family of 
transcription factors. As mice transgenic 
for antioxidant molecules such as catalase 
and thioredoxin have an increased life 
span, and mice deficient in methionine sul-
foxide reductase, an antioxidation enzyme, 
have a decreased life span, these data sup-
port the important role of antioxidants in 
